{
    "links": "https://www.ycombinator.com/companies/ansa-biotechnologies",
    "name": "Ansa Biotechnologies",
    "headline": "Next-generation DNA synthesis using enzymes",
    "batch": "W20",
    "description": "Ansa Biotechnologies is developing a new way to make DNA that will be faster, cleaner, and more accurate than existing methods. Currently, DNA is manufactured via a chemical method that has remained mostly unchanged for 35 years. Our enzyme-based approach promises to dramatically accelerate innovation in biological research and biotechnology, including therapeutics, diagnostics and biomanufacturing.",
    "activity_status": "Active",
    "website": "http://ansabio.com",
    "founded_date": 2018.0,
    "team_size": 72.0,
    "location": "Emeryville, CA",
    "group_partner": "Jared Friedman",
    "group_partner_yc": "https://www.ycombinator.com/people/jared-friedman",
    "company_linkedin": null,
    "company_twitter": null,
    "tags": "industry:synthetic-biology; industry:biotech; location:san-francisco-bay-area",
    "founders": [],
    "status": true,
    "generated_description": "**Ansa Biotechnologies**\n\nFounded in 2018 and based in Emeryville, California, Ansa Biotechnologies is on a mission to revolutionize DNA synthesis by utilizing enzymes instead of traditional chemical methods. This approach not only speeds up the process but also provides a cleaner and more accurate way to produce DNA. For those familiar with the industry, it's worth noting that the existing chemical methods for DNA synthesis have seen little innovation in the past 35 years\u2014until now. \n\nAs a company that emerged from Y Combinator's W20 batch, Ansa has a dedicated team of 72 employees, headed by Jared Friedman, a seasoned Group Partner at Y Combinator. The company is heavily involved in the synthetic biology and biotech sectors, and its innovative technology significantly impacts various fields, including therapeutics, diagnostics, and biomanufacturing. \n\nAnsa\u2019s flagship product, Ansa Clonal DNA, offers reliable and rapid synthesis of complex DNA constructs\u2014up to 5 kilobases in length\u2014enabling scientists to push the boundaries of their research without the usual limitations posed by legacy technologies. Their proprietary enzymatic technology can tackle complex sequences that others often struggle with, such as GC- or AT-rich sequences and CRISPR arrays.\n\nAt its core, Ansa aims to reshape biology. Their work has implications for a wide array of industries, including healthcare, pharmaceuticals, food and agriculture, and industrial biotechnology. As they continue to innovate, they stand ready to empower researchers and drive scientific breakthroughs.\n\nTo learn more about their technology and products, visit their website: [http://ansabio.com](http://ansabio.com).",
    "logo": "https://bookface-images.s3.us-west-2.amazonaws.com/logos/50de62bc8a3288c43f1112f29a29561638bb352a.png?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=ASIAQC4NIECAEHIR6H6F%2F20250221%2Fus-west-2%2Fs3%2Faws4_request&X-Amz-Date=20250221T190959Z&X-Amz-Expires=3600&X-Amz-Security-Token=IQoJb3JpZ2luX2VjELP%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLXdlc3QtMiJIMEYCIQDt736ZW5EfzagAz1eKRSs%2FW4TfHu28RBSFaRNkZ9h47gIhANt6WXtwkgL07bQKDKYDGFxYKx7WOO9JX0BqaYrXnKNbKu4DCNz%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEQABoMMDA2MjAxODExMDcyIgx8TqkMwTM2PLcRmr4qwgPGGtQBXv7gs7%2BXGteI1gQk%2FjkbIHwQ5hCKXJKVmVAPw3MeVLhZyp8Nf5%2FYigbwE%2BrFR7aZWKjrs7HxAE0JWit5dlINZLjZK%2BS%2FwMaCqoj%2BFDN0gw9iiAPu4Xn5c3b%2BuZe%2F5%2Flfk0EuxZAXVsZtShxXZy%2FERPQ0v%2FRZxSz5qUoaXpL1zj6VWdWVzoI7%2FPlB3bgJ2PpiF7DN%2BJeDsJPx%2FoKTo5ehP9pOeGbMNxoeegVJsCJ3zvzO3o4fcZYIf6c5iIJwM1Ot3Gg7Z3v9oLZjSRU%2FaRLL5j4n3II7DaroOCEVfPlWzTyZM7SNFZZAFSKM8vLKj1VdTr9s3How41zluf%2FOIp7sGNhG%2FjuYJoG%2FmkLFIlYP4wbGrLO69AWnenZyfi1UhAiV6N%2BlAqGnqvpOJh4vq8uNh2eRnXR%2BMVXdq9oVYkm7XFgprL5PDC4ULLyBWqA6kca4z7F4H56nkT%2FsDtT8ek2VOIRIv1Zgcz%2BeeVG7F7AHS4bdbR6eZ3ChY1iQhfPBErh4OiFQM7IqiUKw%2B1CTpvL68xcVN5gjiaDH0Jotw%2BUcW9dMSg9py8xH8qgyiWG5w3dDj9xaoA2G3NMYq6JOGKMwwIrjvQY6pAHDH54nhADhmb7YSEGxHkL3pqs%2B6aYOExStWbzLKzRb3lb2DAgGG8uU9COt8%2FqUEOtOcszTKp7yuCJwMVkfI7PDZ74h9uiRkRxjtH7%2BLlE1xrfd%2FrIq%2B%2BZr9hSFqZ9MUQ4yNHesyx2FYDbsIfCW9ntlrpmZUHCcrzpQDfufsAFcpe%2FudVT3tUqiF8WCN1Vd%2Bx%2FQ9d3i1HvBcJWV9AYAwM0W22VM%2BA%3D%3D&X-Amz-SignedHeaders=host&X-Amz-Signature=2bac4ea9a4b34623216c94276daeb560f3c00848b60717293203aed96ef9cb30",
    "social_links": [
        "https://www.linkedin.com/company/ansabio",
        "https://twitter.com/ansabio",
        "https://www.crunchbase.com/organization/ansa-biotechnologies"
    ],
    "logo_path": "data/logos\\Ansa_Biotechnologies_logo.png"
}